STOCK TITAN

Attovia Therapeutics amends CEO option disclosure

The options vest 25% on August 4, 2027, then in equal monthly installments over the following 36 months, subject to continued service.

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4/A

Rhea-AI Filing Summary

Attovia Therapeutics, Inc. (ATTO) reports that President and CEO and director Tao Fu acquired a stock option award covering 538,300 shares of common stock on August 4, 2026. The options have a $17.00 exercise price and expire August 3, 2036. The amendment replaces the Form 4 submitted August 6, 2026, and states that no changes are being reported to Fu’s beneficial ownership.

Insider Fu Tao
Role President and CEO
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) F1 538,300 $0.00 $0.00
Holdings After Transaction: Stock Option (Right to Buy) — 538,300 contracts (Direct)
Footnotes (1)
  1. F1. 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.
Options awarded 538,300 shares Award acquired August 4, 2026
Exercise price $17.00 per share Stock option award
First vesting installment 25% Vests August 4, 2027, subject to continued service
Remaining vesting period 36 months Equal monthly installments, subject to continued service
Option expiration August 3, 2036 Stock option award
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy)"
vest financial
"25% of the options shall vest"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
continued service financial
"subject to continued service to the Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When do ATTO CEO Tao Fu’s options vest?

The options vest 25% on August 4, 2027, with the remaining options vesting in equal monthly installments over the following 36 months, subject to continued service to Attovia Therapeutics through those dates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Fu Tao

(Last)(First)(Middle)
C/O ATTOVIA THERAPEUTICS, INC.
1091 INDUSTRIAL ROAD, SUITE 310

(Street)
SAN CARLOS CALIFORNIA 94070

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Attovia Therapeutics, Inc. [ ATTO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)
08/06/2026
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$1708/04/2026A538,300 (1)08/03/2036Common Stock538,300$0538,300D
Explanation of Responses:
1. 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.
Remarks:
This Form 4 amendment amends the Form 4 filed on August 6, 2026, which reported the Reporting Person's beneficial ownership using the Issuer's CIK number. This Form 4 amendment has been filed under the Reporting Person's CIK and reflects him as the Reporting Person. This filing amends and replaces the original filing in its entirety. No changes have been made or are being reported with respect to the Reporting Person's beneficial ownership of the Issuer's securities.
/s/ Steven Chan, Attorney-in-Fact for Tao Fu10/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading